Ngalaba Mba Nile

Na Disemba 3, 2024, a na-akwado ọgwụ ọhụrụ Zepzelca (lubbinectedin maka ịgba ọgwụ) site na National Medical Products Administration (NMPA) site na mmemme nyocha mbụ. A na-enye ọgwụ a maka ọgwụgwọ ndị okenye nwere obere mkpụrụ ndụ akpa ume nke nwere ọrịa kansa...GỤKWUO»

Na Disemba 31, National Medical Products Administration (NMPA) nke mba China akwadola VYLOYTM (zolbetuximab), yana ọgwụ chemotherapy nke nwere fluoropyrimidine na platinum, maka ọgwụgwọ mbụ nke ndị ọrịa nwere ọrịa epidermal mmadụ nke na-adịghị ewepụ ihe ma ọ bụ nke na-agbasa ahụ...GỤKWUO»

Na Disemba 31, 2024, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Ụlọ ọrụ ahụ") enwetala ikike ahịa na China site na National Medical Products Administration (NMPA) maka ligand1 (PD-L1) nke a haziri maka ọgwụ mgbochi monoclonal ọhụrụ (“mAb”) nke a na-eduzi...GỤKWUO»

C-CAR031 bụ ọgwụgwọ onwe onye, ​​nke GPC3-targeting chimeric antigen receptor T-Cell (CAR-T), nke a na-amụ maka ọgwụgwọ HCC. Ọ dabere na CAR-T ọhụrụ nke GPC3-targeting nke AstraZeneca mepụtara site na iji usoro ha nke na-agbanwe ihe na-adịghị mma na-agbanwe agbanwe-beta receptor II dominant negati...GỤKWUO»

Na Disemba 20, 2024, Ụlọ Ọrụ Nlekọta Ngwaahịa Ahụike Mba nke China (NMPA) akwadola iji DOVBLERON® (taletrectinib adipate capsule), ọgwụ mgbochi ROS1 tyrosine kinase (TKI) nke ọgbọ na-abịa, maka ọgwụgwọ ndị okenye nwere ROS dị elu ma ọ bụ nke metastatic...GỤKWUO»

C-CAR031 bụ ọgwụgwọ GPC3 nke na-elekwasị anya na chimeric antigen receptor T-Cell (CAR-T), nke a na-amụ maka ọgwụgwọ HCC. E gosipụtara ọganihu nyocha nke C-CAR031 na hepatocellular carcinoma (HCC) n'ọnụ na nzukọ kwa afọ nke American Society of Clinical Oncology (ASCO) h...GỤKWUO»

GT101 bụ ọgwụgwọ mkpụrụ ndụ onwe onye nke ejiri TIL gbasaa ma mee ka ọ dịghachi ọhụrụ site na etuto ahụ onye ọrịa. A na-enye ọgwụgwọ ahụ site n'ịchịkọta anụ ahụ etuto ahụ n'aka ndị ọrịa ma wepụta TIL. A ga-eji usoro nrụpụta nke Grit Bio nke StemTe... mee ka TIL ahụ dị elu.GỤKWUO»

Mkpụrụ ndụ TAEST16001 bụ mkpụrụ ndụ T nke ejiri aka ha mepụta nke na-egosipụta njikọ dị elu nke NY-ESO-1-specific T-cell receptor (TCR) na-elekwasị anya na NY-ESO-1 (nke a na-egosipụta n'ọtụtụ etuto ahụ) nke anụ ahụ dị nro dị mma (STS) dịka HLA-A*02:01 si kwuo. Ọmụmụ ihe nke mbụ gbasara ndị ọrịa nwere S dị elu...GỤKWUO»

Na Disemba 04, 2024, enyerela ikike iji ọgwụ ọhụrụ (NDA) maka njikọta nke TYVYT® (injection sintilimab) na ELUNATE® (fruquintinib) na China maka ọgwụgwọ ndị ọrịa nwere kansa endometrial dị elu nwere etuto Mismatch Repair proficient (pMMR) nke nwere ...GỤKWUO»

GC203 bụ ọgwụgwọ TIL ọhụrụ nke gbanwere mkpụrụ ndụ ihe nketa nke na-abụghị nje, nke e mepụtara site na iji ikpo okwu mgbasa mkpụrụ ndụ DeepTIL® nke Juncell Therapeutics na ikpo okwu mgbanwe mkpụrụ ndụ ihe nketa NovaGMP®. DeepTIL® na-eme ka TILs dị ike nke na agaghị achọ ngwakọta IL-2 mgbe etinyere ya,...GỤKWUO»

Glioblastoma Multiforme (GBM) bụ otu n'ime ọrịa kansa kachasị egbu egbu, ihe fọrọ nke nta ka ọ bụrụ ndị ọrịa niile na-enweta nlọghachi dịka ọkwa nlekọta ugbu a maka GBM a chọpụtara ọhụrụ. GBM na-emegharị (rGBM) na-egosi ndụ ọkara nke ihe na-erughị ọnwa 8 yana nhọrọ ọgwụgwọ pere mpe. TX103 bụ CAR-T ce...GỤKWUO»

RD13-02 bụ ngwaahịa mkpụrụ ndụ CAR-T zuru ụwa ọnụ nke na-elekwasị anya na CD7 sitere na ndị na-enye onyinye ahụike, a na-emekwa ya maka ọgwụgwọ nke ọrịa leukemia/lymphoma lymphoblastic acute T-cell nke na-alaghachi azụ ma ọ bụ nke na-adịghị ike (T-ALL/LBL). A na-agbanwe ya site na mkpụrụ ndụ ihe nketa iji zere ọrịa fratricide, ọrịa graft-versus-host (GvHD), na ọrịa host-versus-...GỤKWUO»